ABBV-428

ABBV-428  is a bi-specific protein therapeutic, designed for mesothelin-dependent CD40 activation, that is being investigated in a Phase 1 clinical trial for solid tumors.

Type of Molecule

Biologic

Target

CD40

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Solid Tumors n/a
Phase 1